RPG Life Sciences has outlined a growth strategy that includes a planned semaglutide launch and the possible acquisition of a manufacturing facility in India. According to the company’s plans, it is scouting for a plant and is prepared to spend about Rs 700 crore to Rs 1,000 crore to support expansion.
The move comes as the company looks to strengthen its manufacturing base while building on new product opportunities. A plant purchase in India would give RPG Life Sciences added capacity as it prepares for its next phase of growth and broadens its operating footprint.
The company is also navigating a difficult business environment marked by rising input costs. It has held discussions with 13 international customers to help absorb those higher costs, a step that the report said has been reflected in its financial performance.
Taken together, the semaglutide launch plans, the search for a manufacturing asset, and efforts to manage cost pressures point to a dual strategy: expand future growth drivers while protecting margins in the current market. The developments suggest RPG Life Sciences is trying to balance near-term operating challenges with longer-term investment plans.
